@michbio

The statewide association for Michigan's bio-industry.

 Ann Arbor, Michigan
michbio.org
Joined February 2010
  • Tweets6.3K
  • Following1K
  • Followers1.5K
1.5KMedia
Michigan has the talent, research, and innovation to compete as a life sciences leader. MichBio is gathering input to identify opportunities, address challenges, and strengthen the state's competitive position. Learn more and share your perspective: michbio.org/news/michigan-ha…
9
In the Fall 2026 BioMatters®, discover how WACKER’s Ann Arbor team is advancing silicone and cyclodextrin technologies for healthcare, medical devices and pharmaceuticals. Read more: Read the Fall 2026 issue of BioMatters®. ow.ly/8CUp50ZUApc #MichBio #BioMatters
12
Got plans tonight? Join us for #BioArbor! Connect with Michigan's life sciences community and hear from Louis Cannon, MD, on healthcare innovation, entrepreneurship and investment. Register: michbio.org/events/bioarbor-…
1
28
The Oct. 2026 GBG Report is now available exclusively to MichBio members, featuring 117 federal funding opportunities, forecasts and notices supporting life sciences research and innovation. Access the report: michbio.org/news/october-202…
21
We’re getting closer to BioMixer™ Traverse City! Don’t miss your chance to connect with Michigan’s life sciences community on Thursday, October 15 at Mammoth Distilling. 📅 October 15 | 5:00–7:00 PM 📍 Mammoth Distilling Registration is FREE: ow.ly/vcBV50ZPEMU
19
CMS has finalized its GLOBE drug pricing model, narrowing the original proposal. MichBio and BIO remain concerned about potential impacts on research investment, drug development and U.S. competitiveness. Read more: ow.ly/MzmP50ZW0ot

CMS Finalizes Narrower GLOBE Drug Pricing Model

michbio.org
26
The newly launched National Center to Accelerate Cures aims to advance New Approach Methodologies (NAMs), helping companies strengthen research decisions and accelerate innovation. Learn what this could mean for Michigan's biotechnology industry: ow.ly/lOQ850ZW0mo

New NAM Center Could Help Companies Strengthen Drug Development

michbio.org
15
What will Michigan’s next governor do to strengthen the state’s life sciences industry? MichBio asked both major-party candidates the same questions on innovation, talent, manufacturing, investment and competitiveness. Read their responses: ow.ly/RNC650ZUAaz
16
The Fall 2026 issue of BioMatters® is out now! Explore the people, companies and ideas turning innovation into impact across Michigan’s life sciences industry. Read the issue: issuu.com/michbio/docs/bioma… #MichBio #BioMatters #MichiganLifeSciences

BioMatters® Fall 2026

BioMatters® Fall 2026 — Michigan's premier biotech and life sciences magazine showcasing bioscience companies, innovations, products, and industry leaders. This twice-annual issue delivers in-depth s

issuu.com
11
What does it take to turn healthcare innovation into commercial success? Join Louis Cannon, MD, at #BioArbor Oct. 14 for insights from a physician, entrepreneur & venture investor. Register today: michbio.org/events/bioarbor-… #MichBio
1
1
23
PDUFA VIII could help shape a more predictable and efficient FDA review process for drugs and biologics, with implications for companies across the life sciences industry. Learn more about what the proposed framework could mean for drug developers: ow.ly/iZE550ZKGJv

PDUFA VIII: A Blueprint For A More Predictable FDA

The Prescription Drug User Fee Act, or PDUFA, allows the U.S. Food and Drug Administration (FDA) to collect fees from pharmaceutical and biotechnology companies to help fund its review of new drugs an

michbio.org
1
36
Drug safety meets ecosystem health in “The Coalition,” a new documentary exploring horseshoe crab blood use in drug safety testing and more sustainable alternatives. Sept. 28 | 4:30–6 PM Michigan Theater, Ann Arbor Free, reservations recommended ow.ly/2XkA50ZQClk
26
Join MichBio and Avantor on October 15 at Mammoth Distilling for an evening of networking with Northern Michigan’s life sciences community. 📅 Thursday, October 15 | 5-7 PM 📍 Mammoth Distilling | Traverse City 🎟️ FREE to attend Register: ow.ly/vcBV50ZPEMU
23
Congress has approved a temporary delay to proposed changes to federal grant administration that could have significant implications for universities, research institutions and life sciences companies receiving federal funding. ow.ly/fmc150ZKGFk

Congress Approves Delay of OMB Grant Overhaul

Congress has approved a continuing resolution that would temporarily block the Office of Management and Budget (OMB) from implementing its proposed overhaul of federal grant administration. 

michbio.org
14
A new information-sharing agreement between the FDA and SEC could bring greater scrutiny to how biotech and pharmaceutical companies communicate clinical and regulatory developments to investors. ow.ly/wsUk50ZKGu3

FDA–SEC Agreement Raises the Stakes For Biotech Investor Disclosures

The U.S. Food and Drug Administration (FDA) and Securities and Exchange Commission (SEC) have signed a first-of-its-kind memorandum of understanding (MOU) that could bring greater scrutiny to how phar

michbio.org
1
22
Great conversations. New connections. Timely topics. #BioArbor returns Sept. 23 with a conversation on AI patentability and what the rapidly evolving technology means for innovators and intellectual property strategy. Learn more: michbio.org/events/bioarbor-…
1
20
What should life science companies be thinking about over the next 12 months? That’s one of the questions our preferred providers will answer during Savings Week Sept. 16–17. Register: ow.ly/oO6350ZGbkx
8
MichBio is proud to host the 2026 CSBA-SMTA Midwest Directors' Retreat this week on Mackinac Island. Thank you to our sponsors—VWR, AdvaMed, BIO, PhRMA, Genentech, Novartis, and Johnson & Johnson—for supporting this gathering of Midwest bioscience leaders. #MichBio
42
The Sept. GBG Report by G2G - Innovative Government Affairs Consulting includes 91 funding opportunities, forecasts, notices of special interest, requests for information, and other funding resources relevant to life sciences organizations. Details: ow.ly/oC4w50ZMBo4
24
Most-favored-nation drug pricing is expanding beyond the largest pharmaceutical companies. What could that mean for emerging biotechs? We look at the potential implications for startup valuations, licensing strategies, manufacturing and investment: michbio.org/news/mfn-deals-m…

MFN Deals Move Beyond Big Pharma - What it Means For Biotech Startups

The White House’s agreements with nine additional manufacturers signal that pricing pressure is extending deeper into the biopharmaceutical sector. 

michbio.org
24
Load more